（投资中国）2030年前阿斯利康拟在华投资超1000亿元

Group 1 - AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030 to expand its presence in drug production and R&D [1] - The investment aims to enhance the company's capabilities in cell therapy and radiolabeled drugs, benefiting patients with cancer, blood diseases, and autoimmune diseases [1] - The investment will deepen AstraZeneca's R&D presence in China, including global strategic R&D centers in Beijing and Shanghai, which collaborate with over 500 clinical hospitals [1] Group 2 - The company will upgrade its production bases in Wuxi, Taizhou, Qingdao, and Beijing, with plans to announce new production facilities [1] - Existing facilities are currently providing innovative medicines to patients in China and over 70 global markets [1] - The investment is expected to increase AstraZeneca's workforce in China to over 20,000 employees and create thousands of new jobs in the healthcare ecosystem [1]